Focus: Dogwood Therapeutics is a public biotechnology company focused on small molecule development for neurological indications. The company operates at mid-cap scale with 501-1000 employees headquartered in Alpharetta, Georgia.
Profile data last refreshed 21h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Dogwood Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Dogwood Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Dogwood Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
[ARS] Dogwood Therapeutics, Inc. SEC Filing - Stock Titan
[ARS] Dogwood Therapeutics, Inc. SEC Filing Stock Titan
Big capital authorization vote ahead for Dogwood Therapeutics (NASDAQ: DWTX) - Stock Titan
Big capital authorization vote ahead for Dogwood Therapeutics (NASDAQ: DWTX) Stock Titan
Dogwood licenses Long-COVID antiviral assets in pact worth up to $100M - Stock Titan
Dogwood licenses Long-COVID antiviral assets in pact worth up to $100M Stock Titan
Dogwood Therapeutics Announces Worldwide Development and - GlobeNewswire
Dogwood Therapeutics Announces Worldwide Development and GlobeNewswire
DWTX (Dogwood Therapeutics Inc.) posts far narrower Q4 2025 loss than consensus estimates, yet shares dip 4.47% today. - Momentum Score - Cổng thông tin điện tử Tỉnh Sơn La
DWTX (Dogwood Therapeutics Inc.) posts far narrower Q4 2025 loss than consensus estimates, yet shares dip 4.47% today. - Momentum Score Cổng thông tin điện tử Tỉnh Sơn La
DWTX (Dogwood Therapeutics Inc.) posts far narrower Q4 2025 loss than consensus estimates, yet shares dip 4.47% today. - High Interest Stocks - UBND thành phố Hải Phòng
DWTX (Dogwood Therapeutics Inc.) posts far narrower Q4 2025 loss than consensus estimates, yet shares dip 4.47% today. - High Interest Stocks UBND thành phố Hải Phòng
Showing 6 of 10 news items
No open positions listed yet.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo